In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

Executive Summary

With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.


Related Content

Generics In Europe: Search For Greener Pastures?
US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing
Opko Embarks On Transition To Profitability With Discount Buy
OPKO bags US’ No 3 clinical lab operator for $1.47bn
Another Pfizer deal: Opko's once-weekly growth hormone
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts